GlassScriptPhysician profile
Beenu Kaw
NPI 1790700375
$4,053.76
in general payments reported to CMS, 2019-2025
32 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $260 · 2021: $423 · 2022: $896 · 2023: $507 · 2024: $347 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366 · Education: $18.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.28 |
| Education | $18.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $379.51 | 2021-2023 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $341.66 | 2019-2023 | Farxiga |
| Akebia Therapeutics INC | $307.60 | 2019-2021 | |
| Amgen INC. | $304.74 | 2019-2025 | Tavneos |
| Boston Scientific Corporation | $251.27 | 2020-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $181.42 | 2022-2023 | |
| Shire North American Group INC | $166.53 | 2019 | |
| Edwards Lifesciences Corporation | $142.76 | 2025 | Sapien 3 Ultra Resilia |
| Ardelyx, INC. | $142.64 | 2025 | Xphozah 30 Mg |
| Mallinckrodt Enterprises LLC | $131.31 | 2019 | |
| Travere Therapeutics, INC. | $127.08 | 2022-2023 | |
| Vifor Pharma, INC. | $125.65 | 2019-2023 | Veltassa |
| Merck Sharp & Dohme LLC | $124.71 | 2024 | Prevymis |
| Aurinia Pharma U.S., INC. | $123.08 | 2021-2022 | |
| Novo Nordisk INC | $120.89 | 2024 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $120.09 | 2019-2023 | Velphoro |
| Glaxosmithkline, LLC. | $119.27 | 2021-2023 | Benlysta |
| Horizon Therapeutics Plc | $108.39 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.60 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $96.24 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $76.44 | 2019-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $73.61 | 2021-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $65.45 | 2020-2023 | Jynarque |
| Janssen Pharmaceuticals, INC | $53.81 | 2019 | |
| Calliditas Therapeutics US INC. | $48.34 | 2022 | |
| Ani Pharmaceuticals, INC. | $45.58 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $42.14 | 2019-2020 | |
| Amicus Therapeutics, INC. | $39.48 | 2019-2020 | |
| Genzyme Corporation | $36.06 | 2019 | |
| Daiichi Sankyo INC. | $31.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.50 | 2019 | |
| Nxstage Medical, INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beenu Kaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.